The new funding will allow the biotech company to advance its programs and accelerate the development of life-saving treatments for neurodegenerative diseases.
Bristol Myers Squibb is dropping $920 million to acquire the exclusive global rights of Immatics’ experimental cancer drug program, the companies announced Tuesday morning.
1E Therapeutics announced $120 million seed funding, a remarkable feat for an early-stage biotech company. The funding is the largest of its kind for an Israeli biotech company.
On Wednesday, clinical-stage biotech Avistone Pharmaceuticals announced that it has raised more than $200 million of financial backing to support its business combination with Pearl Biotechnology.
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
The company said the study demonstrated broad efficacy, showing statistically significant superiority to placebo over a total of 15 prespecified primary and secondary outcome measures.
